Works by Sun Jin Sym

Results: 43
    1
    2
    3
    4
    5
    6

    Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211042812
    By:
    • Han, Hye Sook;
    • Kim, Bum Jun;
    • Jee, Hee-Jung;
    • Ryu, Min-Hee;
    • Park, Se Hoon;
    • Rha, Sun Young;
    • Kim, Jong Gwang;
    • Bae, Woo Kyun;
    • Lee, Keun-Wook;
    • Oh, Do-Youn;
    • Kim, In-Ho;
    • Sym, Sun Jin;
    • Oh, So Yeon;
    • Kim, Hyeong Su;
    • Byun, Ji-Hye;
    • Kim, Dong Sook;
    • Suh, Young Ju;
    • An, Hyonggin;
    • Zang, Dae Young
    Publication type:
    Article
    7

    Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211042812
    By:
    • Han, Hye Sook;
    • Kim, Bum Jun;
    • Jee, Hee-Jung;
    • Ryu, Min-Hee;
    • Park, Se Hoon;
    • Rha, Sun Young;
    • Kim, Jong Gwang;
    • Bae, Woo Kyun;
    • Lee, Keun-Wook;
    • Oh, Do-Youn;
    • Kim, In-Ho;
    • Sym, Sun Jin;
    • Oh, So Yeon;
    • Kim, Hyeong Su;
    • Byun, Ji-Hye;
    • Kim, Dong Sook;
    • Suh, Young Ju;
    • An, Hyonggin;
    • Zang, Dae Young
    Publication type:
    Article
    8
    9
    10
    11

    Erratum to: Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

    Published in:
    2017
    By:
    • Kim, Jeong;
    • Jang, Joung-Soon;
    • Kim, Jae-Weon;
    • Lee, Sung;
    • Cho, Chi-Heum;
    • Lee, Myung-Ah;
    • Kim, Do-Jin;
    • Ahn, Myung-Ju;
    • Lee, Kil;
    • Sym, Sun;
    • Lim, Myong;
    • Jung, Hun;
    • Kim, Cho;
    • Min, Kyung;
    • Kim, Jeong Eun;
    • Lee, Sung Yong;
    • Lee, Kil Yeon;
    • Sym, Sun Jin;
    • Lim, Myong Choel;
    • Kim, Cho Eun
    Publication type:
    journal article
    12

    Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

    Published in:
    2017
    By:
    • Kim, Jeong;
    • Jang, Joung-Soon;
    • Kim, Jae-Weon;
    • Sung, Yong;
    • Cho, Chi-Heum;
    • Lee, Myung-Ah;
    • Kim, Do-Jin;
    • Ahn, Myung-Ju;
    • Lee, Kil;
    • Sym, Sun;
    • Lim, Myong;
    • Jung, Hun;
    • Cho, Eun;
    • Min, Kyung;
    • Kim, Jeong Eun;
    • Sung, Yong Lee;
    • Lee, Kil Yeon;
    • Sym, Sun Jin;
    • Lim, Myong Choel;
    • Cho, Eun Kim
    Publication type:
    journal article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

    Published in:
    Gastric Cancer, 2024, v. 27, n. 6, p. 1287, doi. 10.1007/s10120-024-01535-0
    By:
    • Boku, Narikazu;
    • Omori, Takeshi;
    • Shitara, Kohei;
    • Sakuramoto, Shinichi;
    • Yamaguchi, Kensei;
    • Kato, Ken;
    • Kadowaki, Shigenori;
    • Tsuji, Kunihiro;
    • Ryu, Min-Hee;
    • Oh, Do-Youn;
    • Oh, Sang Cheul;
    • Rha, Sun Young;
    • Lee, Keun-Wook;
    • Chung, Ik-Joo;
    • Sym, Sun Jin;
    • Chen, Li-Tzong;
    • Chen, Jen-Shi;
    • Bai, Li-Yuan;
    • Nakada, Takashi;
    • Hagihara, Shunsuke
    Publication type:
    Article
    32

    Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

    Published in:
    Gastric Cancer, 2018, v. 21, n. 5, p. 819, doi. 10.1007/s10120-018-0806-1
    By:
    • Jung, Minkyu;
    • Ryu, Min-Hee;
    • Oh, Do Youn;
    • Kang, Myounghee;
    • Zang, Dae Young;
    • Hwang, In Gyu;
    • Lee, Keun-Wook;
    • Kim, Ki Hyang;
    • Shim, Byoung Yong;
    • Song, Eun Kee;
    • Sym, Sun Jin;
    • Han, Hye Sook;
    • Park, Young Lee;
    • Kim, Jin Soo;
    • Lee, Hyun Woo;
    • Lee, Moon Hee;
    • Koo, Dong-Hoe;
    • Song, Hong Suk;
    • Lee, Namsu;
    • Yang, Sung Hyun
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma.

    Published in:
    Oncology (08909091), 2023, v. 37, n. 4, p. 175
    By:
    • Catenacci, Daniel V. T.;
    • Yoon-Koo Kang;
    • Uronis, Hope E.;
    • Keun-Wook Lee;
    • Ng, Matthew C. H.;
    • Enzinger, Peter C.;
    • Se Hoon Park;
    • Gold, Philip J.;
    • Lacy, Jill;
    • Hochster, Howard S.;
    • Sang Cheul Oh;
    • Yeul Hong Kim;
    • Marrone, Kristen A.;
    • Kelly, Ronan J.;
    • Juergens, Rosalyn A.;
    • Jong Gwang Kim;
    • Alcindor, Thierry;
    • Sun Jin Sym;
    • Eun-Kee Song;
    • Cheng Ean Chee
    Publication type:
    Article
    42
    43